Trial Profile
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Metronidazole
- Indications Gram-negative infections; Intra-abdominal infections; Urinary tract infections
- Focus Registrational; Therapeutic Use
- Acronyms REPRISE
- Sponsors AstraZeneca
- 13 Sep 2023 Results of a pooled post-hoc analysis from following clinical studies: NCT01499290, NCT01726023, NCT01644643, NCT01595438, NCT01599806 and NCT01808092 assessing clinical and microbiological outcomes and safety in patients with infections caused by beta-lactamase-producing Gram-negative pathogens published in the Journal of Antimicrobial Chemotherapy
- 25 Oct 2020 Results assessing anti-microbial activity ceftazidime-avibactam and comparator agents against enterobacterales and pseudomonas aeruginosa with overexpression of AmpC beta-lactamase from phase 3 studies (RECLAIM , REPRISE, RECAPTURE & REPROVE), presented at the IDWeek 2020.
- 29 Jun 2020 Results evaluating the safety of ceftazidime-avibactam in adults published in the Drug Safety